All In Biotech

Free tool

FAERS Monitor: Ivra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217110 or its brand name (Ivra, Melphalan Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

13

Serious

12

92% of reports

Hospitalization

4

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death3
  • acute kidney injury1
  • adenovirus infection1
  • aspiration1
  • atrial fibrillation1
  • blood creatinine increased1
  • cardiomyopathy1
  • colitis1
  • deep vein thrombosis1
  • diarrhoea1
  • dry eye1
  • enterocolitis infectious1
  • fall1
  • fatigue1
  • febrile neutropenia1

Reports by year received

View as table
YearReports
20143
20151
20162
20173
20204

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,146 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
enterocolitis infectious11756.6266.9438
adenovirus infection1558.184.9138
aspiration1147.722.536
cardiomyopathy1109.516.726
colitis142.76.510
dry eye132.44.97
deep vein thrombosis124.93.85
blood creatinine increased124.83.85
febrile neutropenia124.43.75
atrial fibrillation116.62.53
acute kidney injury110.61.62
deathSignal35.62.18
fall14.90.70
diarrhoea12.50.40
fatigue12.10.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.